为肝细胞癌武装 GPC3 CAR-T 细胞:多少才足够,下一步是什么?
Armouring GPC3 CAR T cells for hepatocellular carcinoma: how much is enough and what comes next?
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:METTL3-Driven m6A Modification of Cpt1a Gene in High Fat Diet Related Liver Cancer Tumor Macrophages Facilitates Type II Macrophage Differentiation.
METTL3-Driven m6A Modification of Cpt1a Gene in High Fat Diet Related Liver Cancer Tumor Macrophages Facilitates Type II Macrophage Differentiation.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
我们的研究发现,高脂饮食会增强肿瘤巨噬细胞中 METTL3 驱动的肉碱棕榈酰转移酶 1A(CPT1A)m6A 修饰,促进 II 型巨噬细胞分化,并加剧肝癌生长和免疫逃逸。
肥胖会诱发慢性炎症和激素失衡,从而促进肿瘤生长。本研究探讨高脂饮食下肿瘤相关巨噬细胞较少被了解的动态变化及其对肿瘤生长的影响,重点阐明高脂饮食对肝癌中巨噬细胞行为的作用。
我们通过高脂饮食结合肝癌植入方法建立了小鼠肥胖模型。分离肿瘤浸润巨噬细胞进行分析。我们通过转录组学和代谢组学研究探讨了高脂饮食对巨噬细胞的具体影响,并进一步利用体外和体内模型探究了N6-甲基腺苷(m6A)RNA修饰对巨噬细胞分化的影响。
我们的研究结果表明,高脂饮食显著加速原位肝癌生长,并促进肿瘤相关巨噬细胞的II型分化。RNA测序显示Cpt1a和Mettl3基因上调,这两个基因对巨噬细胞中的m6A修饰至关重要。利用Mettl3表达升高或Cpt1a基因敲除的人和小鼠巨噬细胞系,我们证明甲基转移酶样3(METTL3)增强巨噬细胞中的脂肪酸代谢,这一过程可通过Cpt1a基因敲除逆转。这些效应在体内得到证实。此外,输注高Mettl3表达的巨噬细胞,结合原位植入模型和过继细胞疗法,显著促进肝癌生长并增加II型巨噬细胞分化(p < 0.001)。与对照组相比,Cpt1a基因敲除抵消了METTL3效应(p > 0.05)。METTL3和m6A RNA免疫沉淀(RIP)实验证实METTL3稳定Cpt1a mRNA。此外,临床标本的多光谱染色显示,肝癌肿瘤相关巨噬细胞中METTL3蛋白水平与M2巨噬细胞比例呈正相关,与M1巨噬细胞呈负相关(p < 0.01)。巨噬细胞中高Mettl3表达与肝癌患者不良预后相关,并与肿瘤大小和肿瘤淋巴结转移(TNM)分类分期显著相关。
Obesity induces chronic inflammation and hormonal imbalances that contribute to tumor growth. This study explores the less understood dynamics of tumor-related macrophages under a high-fat diet and its consequent impact on tumor growth, with a focus on elucidating the role of high-fat diets on macrophage behavior in liver cancer.
We established a mouse obesity model using a high-fat diet, combined with a liver cancer implantation approach. Tumor-infiltrating macrophages were isolated for analysis. We investigated the specific effects of a high-fat diet on macrophages through transcriptomic and metabolomic studies and further explored the influence of N6-methyladenosine (m6A) RNA modification on macrophage differentiation using in vitro and in vivo models.
Our findings reveal that a high-fat diet significantly accelerates in-situ liver cancer growth and fosters type II differentiation of tumor-associated macrophages. RNA sequencing indicated upregulation of Cpt1a and Mettl3 genes, which are crucial for m6A modification in macrophages. Using human and mouse macrophage cell lines with either elevated Mettl3 expression or Cpt1a gene knockout, we demonstrated that methyltransferase-like 3 (METTL3) enhances fatty acid metabolism in macrophages, a process reversible by Cpt1a gene knockout. These effects were corroborated in vivo . Further, macrophages infused with high Mettl3 expression, when combined with an in-situ implantation model and adoptive cell therapy, markedly promoted liver cancer growth and increased type II macrophage differentiation ( p < 0.001). Knockout of the Cpt1a gene counteracted the METTL3 effect compared to the control group ( p > 0.05). METTL3 and m6A RNA Immunoprecipitation (RIP) assays confirmed that METTL3 stabilizes Cpt1a mRNA. Additionally, multispectral staining of clinical specimens revealed a positive correlation between METTL3 protein levels in liver cancer tumor-associated macrophages and M2 macrophage prevalence, inversely correlating with M1 macrophages ( p < 0.01). High Mettl3 expression in macrophages was associated with poor prognosis in liver cancer patients, correlating significantly with tumor size and tumor node metastasis (TNM) classification stage.
Our research identifies that a high-fat diet elevates METTL3-driven m6A modification of carnitine palmitoyltransferase 1A (CPT1A) in tumor macrophages, fostering type II macrophage differentiation, and exacerbating liver cancer growth and immune evasion.
MEMBER ACCOUNT
登录成功会直接打开下一页。